1-3 of 3
Chiara Nozzoli, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Michele Cavo, M.D., Sara Bringhen, M.D., Nicoletta Testoni, B.S., Paola Omedè, B.S., Giulia Marzocchi, B.S., Marina Ruggeri, B.S., Sandra Durante, B.S., Francesco Di Raimondo, M.D., Davide Rossi, M.D., Ausilia Gorgone, M.D., Francesca Patriarca, M.D., Maria Teresa Petrucci, M.D., Silvia Buttignol, M.D., Anna Levi, M.D., Massimo Offidani, M.D., Chiara Nozzoli, M.D., Roberto Ria, M.D., Barbara Olivero, M.D., Monica Galli, M.D., Vittorio Montefusco, M.D., Vincenzo Callea, M.D., Antonietta Falcone, M.D., Antonio De Vivo, M.D., Mario Boccadoro, MD, Carolina Terragna, B.S., Antonio Palumbo, M.D.
Journal: Blood
Blood (2009) 114 (22): 1868.
https://doi.org/10.1182/blood.V114.22.1868.1868
Published: 2009
Journal Articles

A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.

Michele Cavo, M.D., Paola Tacchetti, M.D., Francesca Patriarca, M.D., Maria Teresa Petrucci, M.D., Lucia Pantani, M.D., Monica Galli, M.D., Francesco Di Raimondo, M.D., Claudia Crippa, M.D., Sara Bringhen, M.D., Massimo Offidani, M.D., Franco Narni, M.D., Vittorio Montefusco, M.D., Elena Zamagni, M.D., Tonino Spadano, M.D., Norbert Pescosta, M.D., Luca Baldini, M.D., Claudia Cellini, M.D., Tommaso Caravita, M.D., Antonio Ledda, M.D., Antonietta Falcone, M.D., Patrizia Tosi, M.D., Chiara Nozzoli, M.D., Renato Zambello, M.D., Luciano Masini, M.D., Paola Agostini, M.D., Mauro Fiacchini, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2009) 114 (22): 351.
https://doi.org/10.1182/blood.V114.22.351.351
Published: 2009
Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Michele Cavo, M.D., Nicoletta Testoni, B.S., Carolina Terragna, B.S., Giulia Marzocchi, B.S., Sandra Durante, B.S., Renato Zambello, M.D., Chiara Nozzoli, M.D., Lucia Pantani, M.D., Paola Tacchetti, M.D., Luciano Masini, M.D., Michela Ceccolini, M.D., Paola Agostini, M.D., Elena Zamagni, M.D., Valerio De Stefano, M.D., Patrizia Tosi, M.D., Daniele Derudas, M.D., Laura Dessanti, M.D., Stelvio Ballanti, M.D., Salvatore Palmieri, M.D., Andrea Nozza, M.D., Gioacchino Catania, M.D., Jacopo Peccatori, M.D., Alfonso D’Arco, M.D., Pellegrino Musto, M.D., Mariella Grasso, M.D., Maria Caterina Pallotti, M.D., Silvana Pasini, M.D., Pier Paolo Fattori, M.D., Anna Baraldi, M.D., Delia Cangini, M.D., Filippo Ballerini, M.D., Alessandro Petrucci, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2008) 112 (11): 1662.
https://doi.org/10.1182/blood.V112.11.1662.1662
Published: 2008